Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAK | O14976 | 3/20 | 0.30 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.30 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.30 |
| ▸ | STK16 | O75716 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478732 | 1.00 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2KDM4EALDH1A1PTGS1 | |
| SCHEMBL20299141 | 0.83 | KDM4E (0.35) | SMN1; SMN2KDM4EALDH1A1PTGS1PTGS2 | |
| SCHEMBL29426991 | 0.79 | SMN1; SMN2 (0.41) | HSD17B10SMN1; SMN2KDM4EALDH1A1PTGS1 | |
| SCHEMBL571943 | 0.79 | SMN1; SMN2 (0.41) | HSD17B10SMN1; SMN2KDM4EALDH1A1PTGS1 | |
| SCHEMBL23916519 | 0.79 | KDM4E (0.33) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16009116 | 0.79 | KDM4E (0.33) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31753134 | 0.79 | KDM4E (0.33) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11996635 | 0.78 | CCR1 (0.45) | HSD17B10SMN1; SMN2KDM4EALDH1A1CCR1 | |
| SCHEMBL20875536 | 0.78 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1PTGS1PTGS2 | |
| SCHEMBL29620499 | 0.78 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210047340-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | CAPULUS THERAPEUTICS, LLC | 2021-02-18 | — | — | US | disclosed |
| CN-112243374-A | SREBP inhibitors comprising a 6-membered central ring | 卡普勒斯疗法有限责任公司 | 2021-01-19 | — | — | CN | disclosed |
| EP-3746070-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | Capulus Therapeutics, LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2019148125-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | CAPULUS THERAPEUTICS, LLC (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | HSD17B10 226/4885SMN1; SMN2 4012/4885KDM4E 3805/4885 |
| US-20210047340-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | SREBF1, SREBF2, XBP1 | HSD17B10 226/4885SMN1; SMN2 4012/4885KDM4E 3805/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | HSD17B10 2038/4885SMN1; SMN2 423/4885KDM4E 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.